Department of Surgery, Hillerød Hospital, DK-3400 Hilleroed, Denmark.
Anticancer Res. 2010 Jan;30(1):233-7.
Tissue inhibitor of metalloproteinases-1 (TIMP-1) has been suggested to be a valuable marker in colorectal cancer (CRC), but the effects of chemotherapy on TIMP-1 levels are unknown. The present study evaluated the effect of chemotherapy on TIMP-1 levels in comparison with carcinoembryonic antigen (CEA) levels in patients with stage III colon cancer.
Thirty patients who had been curatively resected for stage III colon cancer were included. The patients received 10-12 cycles of modified FOLFOX6 regimen. Blood samples were collected before and after the first and the second cycle and three months later.
No significant change could be detected in CEA levels while TIMP-1 raised significantly after the second cycle but returned to normal 3 months later.
Plasma CEA levels are stable during adjuvant chemotherapy while the plasma level of TIMP-1 might be directly affected by chemotherapy represented by a transient rise about 2 weeks following the initiation of treatment.
组织金属蛋白酶抑制剂-1(TIMP-1)已被认为是结直肠癌(CRC)有价值的标志物,但化疗对 TIMP-1 水平的影响尚不清楚。本研究评估了化疗对 III 期结肠癌患者 TIMP-1 水平的影响,并与癌胚抗原(CEA)水平进行了比较。
纳入 30 例接受根治性切除术的 III 期结肠癌患者。患者接受 10-12 个周期改良 FOLFOX6 方案。在第一和第二周期以及三个月后采集血液样本。
CEA 水平无明显变化,而 TIMP-1 在第二周期后显著升高,但 3 个月后恢复正常。
辅助化疗期间 CEA 水平稳定,而 TIMP-1 水平可能直接受到化疗的影响,表现为治疗开始后约 2 周内短暂升高。